The International Myeloma Foundation (IMF) Amplifies #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2023
LOS ANGELES, Aug. 24, 2023 (GLOBE NEWSWIRE) -- In 2010, the U.S. Congress designated September as Blood Cancer Awareness Month...
Clinical Trial
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million...
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company...
STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X
HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug....
LumiraDx Reports Second Quarter 2023 Results
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today...
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage...
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor
CHINO HILLS, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical...
EDAP Announces Second Quarter 2023 Financial Results
- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD...
BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases
INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP...
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and...
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a...
Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression
World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /...
AlzeCure Publishes its Interim Report for January – June 2023
STOCKHOLM, SE / ACCESSWIRE / August 24, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR)...
SmartLabs Sets Roadmap for the Future of Science with New, End-to-End R&D Support
New South San Francisco Location Offers CleanSuites, Broadening Scope of Lab Capabilities to Span Early-Stage R&D through Product CommercializationBOSTON, MA...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated...
U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified...